MarketCap
Facebook
X
Telegram
SpringWorks Therapeutics EBITDA | SWTX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA SpringWorks Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -275 M | -341 M | -280 M | -173 M | -46 M | -59 M | -18.5 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.5 M | -341 M | -170 M |
Quarterly EBITDA SpringWorks Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -79.4 M | - | - | - | -93.2 M | - | - | - | -77.4 M | - | -71.2 M | -69 M | -61.4 M | - | -40.6 M | -47 M | -29.6 M | - | -21.4 M | -19.7 M | -16.1 M | -17.4 M | -15.2 M | -14.8 M | -11.7 M | -6.45 M | -5.22 M | -4.22 M | -2.59 M | -4.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.59 M | -93.2 M | -33.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-30.6 M | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.8 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
-137 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-29.2 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-270 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-135 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-214 M | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
15.8 B | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-11.1 M | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
21.1 M | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
780 M | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
8.17 M | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
901 M | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-68.1 M | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
10.4 B | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
1.19 B | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-44.9 M | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-47.3 M | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-1.24 B | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
7.5 B | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-4.55 M | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-35.9 M | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-17.8 M | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-22.5 M | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-9.76 M | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-150 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-513 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-2.4 M | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
-21.4 M | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
-78.1 M | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
2.11 M | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-57.9 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-6.09 M | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-36.5 M | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
51.1 M | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
-13.3 M | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
-76.6 M | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
3.04 B | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
505 K | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
-25.5 M | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
-5.54 M | $ 0.88 | 3.67 % | $ 11.6 M | USA |